The mice treated with HER2-CAR T cells, either co-expressing or singly expressing CXCR5 and CCR6, exhibited significantly improved long-term tumor control compared to those in the Control-T and HER2-CAR T groups. This evidence concerns the gene ERBB2 and neoplasm.